Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Lung Boost Therapy on Post-mastectomy Postmenopausal

20 de agosto de 2026 actualizado por: Radwa Mohammed Yehia, Ahram Canadian University

Breathing New Life: The Impact of Lung Boost Therapy on Pulmonary Function in Post-mastectomy Postmenopausal Women

The goal of this randomized controlled trial is to compare the influences of a traditional pulmonary rehabilitation program versus a combined program including the Lung Boost device on pulmonary function and quality of life in women with compromised respiratory function.

The study will conducted on 50 female participants aged 50-60 years, including post-unilateral mastectomy and postmenopausal cases.

Participants will be randomly assigned into two (2) groups:

  • Traditional Group (n=25), will receive conventional breathing exercises and the Lung Boost Group (n=25), will receive the same exercises plus Lung Boost respiratory muscle training.
  • Intervention will last 6 weeks 1 session/ day. Pulmonary function parameters (FVC, FEV1, FEV1/FVC, MVV), and quality of life will be assessed pre- and post-treatment.

The main question it aims to answer "Is Lung Boost device has a positive effect on Pulmonary Function in Post-mastectomy Postmenopausal women?" Researchers will compare conventional breathing exercises to Lung Boost respiratory muscle training. to see if Lung Boost device can improve pulmonary function, and quality of life in Post-mastectomy Postmenopausal women.

Descripción general del estudio

Descripción detallada

This randomized controlled trial aims to evaluate and compare the effects of a conventional pulmonary rehabilitation program versus a combined intervention incorporating the Lung Boost device on pulmonary function and quality of life among women with impaired respiratory function.

The study will include fifty (50) female participants aged between 50 and 60 years who have undergone unilateral mastectomy and are in the postmenopausal stage. Participants will be randomly allocated into two equal groups. The Traditional Group (n=25) will receive standard pulmonary rehabilitation consisting of conventional breathing exercises, while the Lung Boost Group (n=25) will receive the same regimen supplemented with respiratory muscle training using the Lung Boost device.

The intervention period will extend over six weeks, with sessions conducted once daily. Outcomes will be assessed both before and after the intervention. Pulmonary function will be evaluated through spirometric measurements, including forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), the FEV₁/FVC ratio, and maximum voluntary ventilation (MVV). In addition, quality of life will be assessed using a validated questionnaire appropriate for the target population.

The study seeks to determine whether the inclusion of the Lung Boost device within a structured pulmonary rehabilitation program yields significant improvements in pulmonary function and overall quality of life in postmastectomy, postmenopausal women with compromised respiratory performance, compared with conventional breathing exercises alone.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

50

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Giza Governorate
      • Giza, Giza Governorate, Egipto, 3220001
        • Ahram Canadian University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Female patients aged between 50 -60 years,
  • post-unilateral mastectomy cases,
  • postmenopausal women,
  • Able to perform breathing exercises and use the Lung Boost device, and cooperative
  • Capable of providing informed consent.

Exclusion Criteria:

  • Severe cardiopulmonary diseases
  • Contraindicating exercise,
  • Cognitive impairments preventing device use,
  • Current smokers Cases with uncontrolled chronic obstructive pulmonary disease (COPD), and cases unable to comply with the training protocol

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Traditional Group (Control)
"Behavioral: Breathing Exercises.

Participants will perform a standardized set of breathing and relaxation exercises consisting of:

Diaphragmatic breathing (approximately 15 minutes) Pursed-lip breathing (approximately 10 minutes) Relaxation techniques (approximately 5 minutes) Frequency & Duration: One session daily, 5 sessions per week, for 6 consecutive weeks.

Session Length: 30 minutes per session. Provider/Setting: Initial instruction and supervision by a licensed physiotherapist; exercises thereafter performed at home with adherence logs.

Safety Monitoring: Participants will be advised to stop if dizziness, chest pain, or unusual shortness of breath occurs, and will report adverse events weekly.

Comparador activo: Lung Boost Group ( (Interventional)
Device: Lung Boost Respiratory Muscle Trainer" AND "Behavioral: Breathing Exercises."

Participants will perform a standardized set of breathing and relaxation exercises consisting of:

Diaphragmatic breathing (approximately 15 minutes) Pursed-lip breathing (approximately 10 minutes) Relaxation techniques (approximately 5 minutes) Frequency & Duration: One session daily, 5 sessions per week, for 6 consecutive weeks.

Session Length: 30 minutes per session. Provider/Setting: Initial instruction and supervision by a licensed physiotherapist; exercises thereafter performed at home with adherence logs.

Safety Monitoring: Participants will be advised to stop if dizziness, chest pain, or unusual shortness of breath occurs, and will report adverse events weekly.

Intervention Type 1: Device (Respiratory Muscle Training) Intervention Name 1: Lung Boost respiratory muscle trainer

Intervention Description 1:

Inspiratory/expiratory muscle training using the Lung Boost device. Training parameters: resistance at 30% of maximal inspiratory pressure progressing up to 60% over 6 weeks].

Frequency & Duration (Device): 15 minutes per session, once daily, 5 days per week, for 6 weeks.

Intervention Type 2: Behavioral (Breathing exercises) Intervention Name 2: Diaphragmatic breathing, Pursed-lip breathing, Relaxation techniques

Intervention Description 2:

Same standardized breathing and relaxation program as the control group (15 + 10 + 5 minutes).

Frequency & Duration (Exercises): 5 sessions per week, for 6 weeks. Session Length (Exercises): 30 minutes per session. Total Daily Time Commitment: Approximately 45 minutes (15 minutes device + 30 minutes breathing exercises).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Forced Vital Capacity (FVC, L) Forced Expiratory Volume in one second (FEV₁, L) FEV₁/FVC ratio (%) Maximum Voluntary Ventilation (MVV, L/min)
Periodo de tiempo: Measurements will be taken at baseline and after 6 weeks of intervention.
These variables are used to quantify respiratory muscle performance and ventilatory efficiency.
Measurements will be taken at baseline and after 6 weeks of intervention.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Chest Expansion (cm)
Periodo de tiempo: Measurements will be taken at baseline and after 6 weeks of intervention.
Assessed using a measuring tape at the level of the xiphoid process to determine thoracic mobility during maximal inspiration and expiration.
Measurements will be taken at baseline and after 6 weeks of intervention.
Functional Assessment of Chronic Illness Therapy-Dyspnea (FACIT-Dyspnea) and FACIT-Functional Limitation scales
Periodo de tiempo: Applied at baseline and after eight weeks of intervention.
Quality of Life sacles using to assess the impact of respiratory limitations on daily activities and overall well-being.
Applied at baseline and after eight weeks of intervention.
Body mass index (BMI, kg/m^2)
Periodo de tiempo: Applied at baseline and after eight weeks of intervention.
Body Mass Index (BMI, kg/m^2) is a screening tool that estimates the total body fat based on height and weight. It is calculated by dividing weight in kilograms by the square of height in meters (BMI = fraction {kg}{m^2})
Applied at baseline and after eight weeks of intervention.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Radwa Mohammed Yehia, Assistant Professor, Ahram Canadian University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de mayo de 2026

Finalización primaria (Actual)

20 de mayo de 2026

Finalización del estudio (Estimado)

30 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

2 de octubre de 2025

Primero enviado que cumplió con los criterios de control de calidad

19 de mayo de 2026

Publicado por primera vez (Actual)

27 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

20 de agosto de 2026

Última verificación

1 de septiembre de 2025

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Ahram Canadian University(ACU)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir